Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LM-302
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : LaNova Medicines
Deal Size : $951.0 million
Deal Type : Acquisition
Sino Biopharmaceutical to Acquire LaNova Medicines for up to $951 million
Details : Upon completion of the acquisition, LaNova will become a wholly owned subsidiary of Sino. Its lead product, LM-302, is being evaluated for the treatment of CLDN18.2-positive gastric cancer.
Product Name : LM-302
Product Type : Antibody
Upfront Cash : Undisclosed
July 15, 2025
Lead Product(s) : LM-302
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : LaNova Medicines
Deal Size : $951.0 million
Deal Type : Acquisition
Reset All
